Gilead Sciences, Inc. (BCBA:GILD)
Argentina · Delayed Price · Currency is ARS | Market Cap | 226.91T +47.4% |
| Revenue (ttm) | 42.73T +2.4% |
| Net Income | 12.35T +1,672.9% |
| EPS | 9,840.49 +1,684.2% |
| Shares Out | n/a |
| PE Ratio | 18.37 |
| Forward PE | 15.38 |
| Dividend | 689.96 (1.41%) |
| Ex-Dividend Date | Mar 13, 2026 |
| Volume | 2,389 |
| Average Volume | 1,096 |
| Open | 48,520 |
| Previous Close | 47,880 |
| Day's Range | 48,480 - 49,400 |
| 52-Week Range | 27,675 - 58,100 |
| Beta | n/a |
| RSI | 42.60 |
| Earnings Date | May 7, 2026 |
About Gilead Sciences
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Descovy, Genvoya, Odefsey, Sunlenca, Symtuza, and YeztugoFor the treatment of HIV-1 infection in patients. It also provides Epclusa, Livdelzi, and Vemlidy to treat chronic hepatitis C virus, primary biliary cholangitis, and chronic hepatitis B virus; Tecartus, a T-cell therapy for the treatment of adult patients; Trodelvy, an inj... [Read more]
Financial Performance
In 2025, Gilead Sciences's revenue was $29.44 billion, an increase of 2.40% compared to the previous year's $28.75 billion. Earnings were $8.51 billion, an increase of 1672.92%.
Financial numbers in USD Financial StatementsNews
Big Pharma M&A set for mega year as patent expiries drive deal urgency
Biotech dealmaking is on pace for a bumper year in 2026, with large drugmakers on an acquisition spree to boost their pipelines ahead of upcoming patent losses.
Gilead Sciences to Present at Upcoming Second Quarter 2026 Investor Conferences
FOSTER CITY, Calif.--(BUSINESS WIRE)-- #GILD--Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its executives will be speaking at the following investor conferences: BofA Securities Health Ca...
Gilead Sciences Transcript: AGM 2026
The meeting covered board elections, approval of executive compensation, and key shareholder proposals, with all board-backed items passing and shareholder proposals failing. Financial highlights included strong HIV sales, new product launches, and continued dividend growth. Strategic acquisitions and a robust pipeline position the company for sustained growth.
U.S. FDA Grants Priority Review of New Drug Application for Gilead's Once-Daily HIV Treatment of Bictegravir Plus Lenacapavir
FOSTER CITY, Calif.--(BUSINESS WIRE)-- #GILD--Gilead Sciences, Inc. (Nasdaq: GILD) today announced the U.S. Food and Drug Administration (FDA) accepted its New Drug Application (NDA) submission for bi...
Gilead Sciences Completes Acquisition of Arcellx Ahead of Potential Commercial Launch of Anito-cel
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced the successful completion of its previously announced acquisition of Arcellx, Inc. (Nasdaq: ACLX). Under the ...
AHF's Gilead Shareholder Resolution Seeks Transparency on Patent Exclusivities
LOS ANGELES--(BUSINESS WIRE)-- #AHFcares--AHF's Gilead Shareholder Resolution Seeks Transparency on Patent Exclusivities.
Gilead Sciences to Release First Quarter 2026 Financial Results on Thursday, May 7, 2026
FOSTER CITY, Calif.--(BUSINESS WIRE)-- #Earnings--Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its first quarter 2026 financial results and guidance will be released on Thursday, May 7, 2...
Gilead Receives All Required Regulatory Approvals for the Acquisition of Arcellx and Extends Tender Offer
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) announced today that all required regulatory approvals have been obtained for its previously announced acquisition of Arcellx...
PEPFAR and The Global Fund Make Additional Investment in Gilead's Lenacapavir for HIV Prevention to Further Expand Access
FOSTER CITY, Calif.--(BUSINESS WIRE)-- #EndHIV--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the U.S. State Department, the United States President's Emergency Plan for AIDS Relief (PEPFA...
Protests: AHF Blasts Gilead Over Extortionate AIDS Drug Pricing
SAN FRANCISCO--(BUSINESS WIRE)-- #AHFcares--Protests: AHF Blasts Gilead Over Extortionate AIDS Drug Pricing.
AHF Slams Gilead for Role in Florida AIDS Drug Crisis
FORT LAUDERDALE, Fla.--(BUSINESS WIRE)-- #AHFcares--AHF Slams Gilead for Role in Florida AIDS Drug Crisis.
Tempus Announces Strategic Collaboration with Gilead to Advance Oncology R&D Through RWE
CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced an expanded, multi-year collaboration with Gilea...
Cartography Biosciences Advances Strategic Oncology Collaboration with Gilead's First Option Target Exercise
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Cartography Biosciences, Inc., a clinical-stage biotechnology company advancing a differentiated pipeline of antibody-based cancer therapies, today announ...
Gilead Sciences Transcript: M&A announcement
Three acquisitions—Tubulis, Ouro, and Arcellx—strengthen the pipeline in oncology, inflammation, and virology, with each bringing differentiated assets and platforms. Deals are financially disciplined, expected to close in Q2 2026, and aim for rapid integration and future growth.
EQT Life Sciences to exit minority stake in Tubulis via sale to Gilead Sciences for up to USD 5.0 billion
Gilead Sciences has entered into a definitive agreement to acquire Tubulis, a private Germany-based, clinical-stage biotechnology company EQT Life Sciences led the Series B2 financing of Tubulis in Ma...
Gilead Adds to Cancer Pipeline With Acquisition Worth Up to $5 Billion
Gilead Sciences agrees to buy German biotech company Tubulis for $3.15 billion upfront and $1.85 billion in contingency payments.
Gilead Sciences to Buy Clinical-Stage Biotech Tubulis for Up to $5 Billion
Gilead Sciences has agreed to buy German clinical-stage biotechnology company Tubulis for up to $5 billion in a deal that bolsters the biopharmaceutical company's oncology pipeline.
Gilead to Acquire Tubulis Adding Potentially Best-in-Class Antibody-Drug Conjugate and Next Generation Platform to Further Strengthen Oncology Pipeline
FOSTER CITY, Calif. & MUNICH--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced it has entered into a definitive agreement to acquire Tubulis GmbH, a private Germany-based, clinica...
Gilead to acquire Tubulis GmbH for up to $5 billion
Gilead said on Tuesday it would acquire private Germany-based Tubulis GmbH for up to $5 billion, boosting the U.S. drugmaker's pipeline with a lucrative class of experimental cancer drugs...
Gilead Extends Tender Offer to Acquire Arcellx
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today extended the expiration of the tender offer to purchase all outstanding shares of common stock of Arcellx. The offer re...
Markets Haven't Changed. These 2 Cheap Dividends Still Rule
Fear is up, markets are down—and we contrarians know that times like these are when we go shopping for cheap dividends.
Gilead to Buy Ouro Medicines for $2.2 Billion. ‘Immune Reset' Is Key to Future Gains.
Gilead plans to develop Ouro's lead drug candidate, gamgertamig, alongside a Belgian pharma company.
Gilead Sciences to Buy Ouro Medicines for Up to $2.18 Billion
Gilead said the deal would bolster its growing inflammation portfolio.
Gilead to buy biotech firm Ouro Medicines in over $2 billion deal
Gilead Sciences said on Monday it would buy privately held biotech firm Ouro Medicines in a deal worth up to $2.18 billion.
Gilead Sciences to Acquire Ouro Medicines to Advance First in Class T Cell Engager Program for Autoimmune Diseases
FOSTER CITY, Calif.--(BUSINESS WIRE)-- #GILD--Gilead Sciences, Inc. (Nasdaq: GILD) announced today it has entered into a definitive agreement to acquire Ouro Medicines, a privately held biotechnology ...